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Background: The third British National Survey of Sexual Attitudes and Lifestyles (Natsal-3) provides 
an opportunity to explore high-risk human papillomavirus (HR-HPV), and uptake of cervical screening 
and HPV vaccination in the general population. 
Methods: Natsal-3, a probability sample survey of men and women aged 16-74, resident in Britain, 
interviewed 8869 women in 2010-12. We explored risk factors for HR-HPV (in urine from 2569 
sexually-experienced women aged 16-44), non-attendance for cervical screening in the past 5 years 
and non-completion of HPV catch-up vaccination. 
Results: HR-HPV was associated with increasing numbers of lifetime partners, younger age, 
increasing area-level deprivation and smoking. Screening non-attendance was associated with 
younger and older age, increasing area-level deprivation (age-adjusted odds ratio 1.91, 95% 
confidence interval, 1.48 to 2.47 for living in most vs. least deprived two quintiles), Asian/Asian 
British ethnicity (1.96, 1.32 to 2.90), smoking (1.97, 1.57 to 2.47) and reporting no partner in the past 
5 years (2.45, 1.67 to 3.61 vs. 1 partner) but not with HR-HPV (1.35, 0.79 to 2.31). Lower uptake of 
HPV catch-up vaccination was associated with increasing area-level deprivation, non-white ethnicity, 
smoking and increasing lifetime partners. 
Conclusions: Socio-economic markers and smoking were associated with HR-HPV positivity, non-
attendance for cervical screening and non-completion of catch-up HPV vaccination. 
Impact:  The cervical screening programme needs to engage those missing HPV catch-up vaccination 
to avoid a potential widening of cervical cancer disparities in these cohorts. As some screening non-
attenders are at low-risk for HR-HPV, tailored approaches may be appropriate to increase screening 
among higher-risk women. 
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Introduction 
In over 99% of cases, cervical cancer is associated with persistent infection with one or more high-
risk human papilloma virus (HR-HPV) genotypes (1).  Every year in Britain approximately 2,900 
women are diagnosed with cervical cancer (2) and it is the most common cancer in women under 35 
years (3). Worldwide the burden of cervical cancer varies substantially and 85% of cases occur in 
low-to-middle income countries (4). In many high-income countries, including Britain, incidence and 
mortality have decreased over the past few decades, since the introduction of cervical cancer 
screening programmes (5). In Britain, cervical screening uptake is high (around 80%) (6) but cervical 
cancer incidence and mortality are higher in more deprived areas (7,8). The two recent Cancer 
Reform Strategies (2011 and 2007) (9,10) have highlighted the need to reduce these inequalities. 
Understanding the burden of HR-HPV prevalence and uptake of cervical cancer prevention 
programmes (HPV immunisation and cervical screening) will help address this aim. 
In Britain, there have been two recent notable changes in cervical cancer control. First, since 1996, 
increases in cervical cancer incidence have been seen in women aged 20-29 years (11), among whom 
screening uptake is lower and declining (12). Changes in both smoking and sexual behaviour may be 
contributing to the upward trend (11). Second, in September 2008, the UK introduced a school-
based HPV immunisation programme against HPV-16/18 (the types associated with over 70% of 
cervical cancers) for girls aged 12 years which has achieved a fairly uniformly high uptake (>80% 
from 2008-12) (13). A catch-up programme was implemented in schools and general practice over 
the first few years for girls aged up to 18 years. Coverage in these catch-up cohorts was lower and 
more variable (13) and showed some tendency to be lower in more deprived areas (14)(15)(16). We 
have already reported that Britain’s third National Survey of Sexual Attitudes and Lifestyles (Natsal-
3) found that women with more partners and those living in more deprived areas were less likely to 
complete the catch-up immunisation schedule (17). 
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If non-participation in cervical screening and HPV immunisation is not independent or participation 
is lower amongst individuals at risk of HR-HPV infection, their effectiveness may be limited. Natsal-3 
provides an opportunity, unique in Britain, to explore individual-level data on participation in 
cervical screening and HPV immunisation in relation to detailed demographic characteristics, sexual 
behaviours and the presence of HR-HPV and to explore overlap between risk factors for HR-HPV 
infection and participation in prevention programmes and thus to inform the provision of future 
services. 
Materials and Methods 
Participants & procedure 
Natsal-3 is a stratified probability sample survey of 8869 women and 6293 men aged 16-74 years, 
resident in Britain. The overall response rate was 57.7%. Interviews were carried out between 
September 2010 and August 2012. Participants were interviewed using computer-assisted personal 
interviewing with computer-assisted self-interview (CASI) for the more sensitive questions. Details of 
the methods have been published previously (18,19).  
Natsal-3 included questions on socio-demographic characteristics, including educational level and 
occupation, allowing derivation of the National Statistics Socio-economic Classification (NS-SEC). 
Area-level deprivation was determined from postcodes using the Index of Multiple Deprivation 
(IMD) (20), a multi-dimensional measure of deprivation. 
Women who reported some sexual experience (although not necessarily a sexual partner) were 
routed into the CASI section of the questionnaire (N=8538) where cervical screening and HPV 
immunisation questions were asked. Women aged 26 years and over at interview (N=5614) were 
asked “When did you last have a cervical smear test?” with the following five answer options: i) I 
have never had one, ii) less than 3 years ago, iii) between 3 and 5 years ago, iv) between 5 and 10 
years ago and v) more than 10 years ago (adapted from (21)).  
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Women eligible for the HPV immunisation programme (those born on or after 01/09/1990, up to 21 
years by the end of the interview period, N=1094) were asked “Have you ever been vaccinated 
against cervical cancer (received HPV vaccination)?” with the following three answer options: i) Yes – 
I have completed three doses of the vaccine, ii) Yes – I have had one or two doses of the vaccine, but 
not all three doses and iii) No. Women who had not been vaccinated and those who had only 
received one or two doses were defined as not having completed the recommended 3-dose 
vaccination course. Women who reported not having been vaccinated were asked whether they had 
been offered the vaccination.  
Urine collection and testing 
Briefly, at the end of the interview a subsample of 16–44 year olds who reported at least one 
lifetime sexual partner were invited to provide a urine sample to be tested for STIs and 60% agreed 
(17). Written consent was provided for testing without return of results (22). Full details of the urine 
collection methods have been described previously (17,18). 
Urine samples from 2569 women were tested for HPV (17). An in house Luminex®-based genotyping 
assay was used for the detection of HPV types (23). HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 and 68 were defined as HR-HPV according to the WHO International Agency for Research on 
Cancer definition (24).   
Ethics 
The Natsal-3 study was approved by the Oxfordshire Research Ethics Committee A [Ref: 
10/H0604/27] (22). 
Statistical analysis 
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Analyses were carried out using Stata (version 13) accounting for the stratification, clustering and 
weighting of the sample. To account for differences in the probability of selection for and response 
to providing a urine sample, an additional weight was applied to the urine data (17,18).  
Logistic regression models were used to explore the factors associated with HR-HPV detection 
(N=2569), non-attendance for cervical screening in the past 5 years (N=5012) and non-completion of 
HPV catch-up vaccination (N=1050). Limited results have been presented previously (17) but are 
expanded here to present a more comprehensive picture of factors associated with HR-HPV and HPV 
catch-up vaccination in the general British female population.  
Women under 26 or over 64 (60 in Scotland), women reporting having had a hysterectomy (N=365; 
who would not be invited for screening) and women reporting no lifetime sexual partners (N=39; 
who are advised that they might decline their screening invitation) were excluded from analyses of 
cervical screening. Factors associated with non-completion of HPV catch-up vaccination are 
presented for eligible women (born before 01/09/1995 (England and Wales) or 01/03/1995 
(Scotland)).  
We hypothesised that cervical screening non-attenders may have differing risk of HR-HPV and 
cervical cancer based on socio-demographics (e.g. ethnicity) and sexual behaviour (e.g. partner 
numbers). We explored the characteristics of women not attending for cervical screening, in order to 
examine how the prevalence of other cofactors for cervical cancer (25) differed by HR-HPV risk. 
We explore the overlap between factors associated with HR-HPV and participation in cervical 
screening and HPV catch-up vaccination. 
Results 
HR-HPV prevalence 
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HR-HPV was detected in urine from 15.9% (95% confidence interval (CI) 14.4-17.5) of women aged 
16-44 years reporting at least one lifetime partner. HR-HPV prevalence declined above age 24 and 
was associated with a number of socio-demographic characteristics (Table 1). Prevalence was higher 
in women not living with a partner, in women of lower socio-economic status, as measured by 
markers including area-level deprivation (age adjusted OR (AOR) 1.37, 1.05-1.80 for those living in 
the most deprived vs. least deprived two quintiles) and NS-SEC; and in those of mixed vs. white 
ethnicity (AOR  2.00, 1.09-3.67). Prevalence was lower in women of Asian/Asian-British ethnicity 
(AOR 0.40, 0.17-0.97). Prevalence did not vary significantly by sexual identity. Prevalence was higher 
in women who smoked (AOR 1.91, 1.49-2.43) or reported binge drinking regularly (AOR 1.80, 1.31-
2.47).  
HR-HPV was strongly associated with markers of more risky sexual behaviour including a younger 
age (≤16 years) at first heterosexual intercourse, increasing numbers of partners over the lifetime 
and in the past 5 years, as well as reporting two or more partners without a condom in the past year 
(AOR 4.31, 2.83-6.55). Prevalence was also higher in women who reported attending a sexual health 
(GUM) clinic (AOR 2.54, 2.00-3.23) or STI diagnosis/es (AOR  2.36, 1.76-3.16) in the past 5 years.  
Cervical screening uptake 
Figure 1A shows the time since last cervical screen in women aged 26-74 years. Overall, 96.8% of 
women aged 26-74 years reported ever having had a cervical screen. Over 70% of women aged 26-
49 reported having attended screening within the last 3 years. Around 90% of women aged 50-64 
years reported having attended for screening within the last 5 years. A notable proportion of 26-29 
and 30-34 year olds reported never having had a cervical screen (12.1% and 5.9%, respectively),.  
Table 2 shows factors associated with non-attendance for cervical screening in the past 5 years in 
women aged 26-64 (those eligible for screening), of which 8.9% (8.0-9.8) were non-attenders. Non-
attendance was associated with a number of socio-demographic characteristics including younger 
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(<30 years) or older (60+ years) age (OR 2.28, 1.72-3.00 and 2.01, 1.32-3.05, respectively, compared 
to those aged 30-39), lower socio-economic status, including area-level deprivation (AOR 1.91, 1.48-
2.47 for most vs. least deprived two quintiles) and having no educational qualifications (AOR 1.95, 
1.43-2.66), and being of Asian/Asian British ethnicity (AOR 1.96, 1.32-2.90). Women self-identifying 
as lesbian were more likely to be non-attenders (AOR 2.94, 1.36-6.38). Non-attendance was also 
strongly associated with being a current smoker (AOR 1.97, 1.57-2.47). The relationship with 
markers of risky sexual behaviour was not consistent. Overall, there was no association with age at 
first heterosexual intercourse or number of lifetime partners, although non-attendance was highest 
in those with one lifetime partner (11.4%). Women reporting no partners in the past 5 years (AOR 
2.45, 1.67-3.61 vs. 1 partner), or no partners without a condom in the past year were more likely to 
be non-attenders. Non-attendance was lower in women who reported using hormonal 
contraceptives in the past year (AOR 0.53, 0.41-0.69) and in those who had ever attended a sexual 
health (GUM) clinic (AOR 0.53, 0.40-0.69) or had an STI diagnosis (AOR 0.49, 0.33-0.71). There was 
no difference in attendance by HR-HPV status overall (AOR 1.35, 0.79-2.31). Stratification of these 
analyses by age (<50 and 50+ years) and lifetime partners (1 and 2+) returned similar associations 
(data not shown). 
There were two distinct groups of non-attending women (Table 3). Overall, a quarter of non-
attenders reported only 1 lifetime partner. A high proportion of these women were of Asian/Asian 
British ethnicity (25.5%, 17.2%-36.1%), few smoked (20.3%, 12.6%-31.1%), less than 1% reported 
first heterosexual intercourse before 16 years and 20.3% (12.6%-31.1%) reported no sexual partner 
in the past 5 years. Prevalence of HR-HPV in those providing a urine sample was 5.2% (1.4%-17.2%). 
In contrast, among the three-quarters of non-attenders reporting 2 or more lifetime partners, 89.6% 
(85.3%-92.7%) were of White ethnicity, 39.8% (34.4%-45.4%) were smokers and 21.7% (17.3%-
26.8%) reported first heterosexual intercourse before 16 years. However, a similar proportion 
reported no partner in the past 5 years (14.5%, 10.6%-19.4%). Prevalence of HR-HPV in non-
attenders providing a urine sample with 2 or more lifetime partners was 20.3% (12.9%-30.5%). This 
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was non-significantly higher than the prevalence in attenders with 2 or more lifetime partners 
(13.3%, 11.3%-15.7%; p=0.079).  
We looked at the reported recent use of healthcare services among non-attenders. Overall, 6.1% 
(4.3%-8.5%) of non-attenders had been to a sexual health (GUM) clinic in the past 5 years, 14.3% 
(11.2%-18.0%) had attended an ante-natal clinic in the past 5 years and 19.2% (15.8%-23.1%) had 
obtained family planning from a clinical source in the past year. In total, 31.7% (27.1%-36.7%) of 
non-attending women had used one or more of these services. Use of healthcare services did not 
vary by lifetime partners. 
HPV vaccine uptake 
HPV catch-up vaccine uptake varied substantially by school year at eligibility (Figure 1B) with 72.9% 
of women eligible at 14 years reporting having received all 3 doses, compared with only 50.6% of 
women eligible at 17 years. In contrast, 89.0% of women in the routine programme reported having 
received all 3 doses (but denominators are small). Few women had received only one or two doses. 
The proportion of women who reported not having been offered the vaccine was higher in the older 
catch-up cohorts.  
Of women eligible for the HPV catch-up immunisation programme, 38.5% reported not having 
completed the vaccination course. This was strongly associated with markers of lower socio-
economic status (Table 4), non-white ethnicity (AOR 2.01, 1.29-3.13) and smoking (AOR 2.61, 1.93-
3.55). Non-completion was also associated with reporting larger numbers of lifetime partners (AOR 
1.70, 1.09-2.63 for 5+ vs. 1 lifetime partner). Among those with at least one lifetime partner, non-
completion was higher in women reporting first heterosexual intercourse before 16 (AOR 1.68, 1.22-
2.30) and unprotected sex with two or more partners in the past year (AOR 1.81, 1.15-2.84). Those 
using hormonal contraception were less likely to be non-completers (AOR 0.47, 0.34-0.67), while 
those attending sexual health (GUM) clinics (AOR 1.49, 1.10 2.02) and ever having been pregnant 
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(AOR 2.94, 2.04-4.23) were more likely to report non-completion. Non-completion was higher in 
women who were HR-HPV positive (AOR 2.33, 1.45-3.74).  
Associations with having had no doses of the vaccine were similar (data not shown), although a 
stronger association was seen with area-level deprivation and slightly weaker associations with 
sexual behaviours, GUM clinic attendance and ever having been pregnant. 
Overlap between factors associated with HR-HPV infection and uptake of cervical screening & HPV 
vaccination  
Figure 2 shows factors associated with HR-HPV infection (vertical axes) plotted against factors 
associated with non-attendance for cervical screening (Figure 2A) and non-completion of HPV 
vaccination (Figure 2B). The top right hand quadrant for each figure indicates increased risk of HR-
HPV infection and lower uptake of the cervical cancer prevention programme. The area of the 
bubble represents the size of the group as a proportion of those eligible for screening. There was 
evidence of overlap of HR-HPV infection risk and cervical screening uptake for some factors (Figure 
2A). Living in more deprived areas and smoking were associated with both HR-HPV infection and 
non-attendance for cervical screening. These factors were also associated with non-completion of 
HPV vaccination (Figure 2B). Associations between smoking and HR-HPV infection, and uptake of 
cervical screening and HPV vaccination persisted after adjustment for area-level deprivation (data 
not shown). In contrast, HR-HPV prevalence was lower in women of Asian/Asian British ethnicity, 
another group less likely to attend for screening (Figure 2A). Women with 5 or more lifetime 
partners and those who reported attending a sexual health (GUM) clinic, had a higher prevalence of 
HR-HPV infection, and were more likely to have attended for cervical screening but less likely to have 
completed HPV vaccination.  
Discussion 
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In this cross-sectional probability-sample survey of the British general population we found markers 
of lower socio-economic status and smoking to be common risk factors for HR-HPV infection and 
non-uptake of both cervical screening and HPV catch-up vaccination. Overall, cervical screening 
attendance was not lower in women reporting more risky sexual behaviours and there was no 
difference in attendance by HR-HPV status. However, our analysis suggests that there are two 
distinct groups of non-attenders, one of which would be considered at higher risk of developing 
cervical cancer due to high prevalence of other lifestyle risk factors such as smoking and early age at 
first sex, whose non-attendance might augment their overall risk of cervical cancer, and one of 
which would be considered lower risk, whose non-attendance might negate their lower lifestyle risk.  
The major strength of this study is that it is a population-based survey with individual-level data 
from a nationally representative sample. We were able to link behavioural and biological data and 
look at risk factors for different outcomes in the same survey. One limitation is the accuracy of self-
reporting, especially of cervical screening (26,27). Our estimates of cervical screening uptake are 
higher than official figures, which estimate 5-year coverage in 2011-12 as 78.6% (6), and one other 
study (28), which asked for year and month of last cervical screen. We believe that social desirability 
bias is unlikely to have had a substantial effect since this question was asked in the self-completion 
part of the questionnaire. However, ‘telescoping’, where an event is remembered as occurring more 
recently than it did, is a strong possibility both for us and other studies (27,29). Any variation in such 
a bias by the socio-demographic or behavioural variables that we report could mean that we have 
over- or under-estimated associations, for example, if telescoping errors were greater amongst more 
educated women, the association between attendance and education would be over-estimated. 
Women may also not be able to accurately report their vaccination status (30) and accurate 
reporting may vary by other variables. Uptake estimates may be affected by biases in the women 
who agreed to participate in Natsal-3. The Natsal-3 response rate was 57.7%, which is comparable 
with other population-based surveys completed around the same time (31,32). After weighting our 
data to match the British population for age, gender and geographic region, the sample was 
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comparable with the 2011 census data on other key demographic characteristics (18). However, 
women who do not attend for screening may be less likely to participate in research studies or 
engage more generally (33).  
Another limitation is that urine is a suboptimum specimen for HPV detection (34) with recent 
estimates of 77% sensitivity of cervical HR-HPV (35) and therefore a likely underestimate of HR-HPV 
prevalence, although this would weaken, not bias, our identification of risk factors. Finally, due to 
the years the Natsal-3 fieldwork was carried out, our study could only focus on the catch-up 
programme, and the factors we describe as associated with vaccination uptake in the catch-up 
cohorts may not be generalizable to routine vaccination at 12 years of age.  
To our knowledge, no population-based studies have examined the associations between cervical 
screening and sexual behaviour or HR-HPV infection. We found lower screening uptake among 
women with lower levels of education and of non-White ethnicity as in other British population 
studies (21,28). Other studies have shown lower uptake of HPV catch-up vaccination in women of 
Black/Black British and Asian/Asian British ethnicity (36,37). Our sample of women of these ethnic 
minorities was too small to examine associations between vaccination and each ethnic group but 
completion of catch-up vaccination was lower in women of non-White ethnicity.  
It is a reasonable expectation that herd immunity should lead to a reduction in cervical cancer 
incidence among unvaccinated women in the catch-up vaccination cohorts (38). However, the effect 
of multiple risks in some groups of women has the potential to widen inequalities in cervical cancer 
incidence. Women who live in more deprived areas and who smoke were less likely to complete 
catch-up vaccination. These women were also at higher risk of HR-HPV and their cervical cancer risk 
is compounded by smoking, which is itself a cofactor in cervical cancer development (39). 
Additionally, these women were less likely to attend for cervical screening, thereby losing the 
opportunity for early detection and treatment of cancer abnormalities. Special efforts may be 
warranted to ensure women who missed vaccination are engaged by the cervical screening 
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programme, especially since girls with low intentions to attend for cervical screening may be less 
likely to be fully-vaccinated (40). Good linkage between vaccination and screening records will be 
important in order to target those not vaccinated. 
As some non-attenders for cervical screening seem to be at low risk for HR-HPV, tailored approaches 
may be appropriate to increase screening among higher risk women. On the other hand there is 
evidence of lower uptake of cervical screening among women who may be considered at lower risk 
for cervical cancer or may perceive themselves to be. For example, as in other studies, we found 
lower uptake in women self-identifying as lesbian (41,42). Previous studies have also found that 
women who are not sexually active are less likely to attend for screening (33). Cervical screening 
prevents approximately 75% of cervical cancers by detecting and treating cervical abnormalities in 
women who attend regularly (5,43). The odds of cervical cancer are approximately six times higher 
in women with no adequate screens at age 50-64 compared to those with adequate negative 
screening (44) so despite being at lower relative risk for cervical cancer, by missing the prevention 
opportunity offered by cervical screening these women may end up at increased risk. Although they 
have a lower incidence of cervical cancer overall, Asian/Asian British women aged 65 and over have 
a higher incidence than do women of White ethnicity (45). Since these women are unlikely to access 
sexual health services, engaging them in screening through general practice (family doctor) is 
important. The cervical screening programme also needs to counter this risk-based tendency for 
non-participation. This will be particularly important in the era of vaccination, where careful 
messaging will be needed to promote uptake of screening among those who may perceive 
themselves at less risk. 
Overall those at increased risk of HR-HPV were no more or less likely to attend for screening. We 
found markers of engagement with healthcare, such as sexual health (GUM) clinic attendance and 
using hormonal contraception, were associated with higher cervical screening attendance. In 2011-
12, 17% of women having a cervical screen in England had a test which was outside the invitation 
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system of the cervical screening programme, i.e. opportunistic tests which were initiated by the 
person taking the sample or by the woman (46). This underlines the importance of maintaining 
integrated sexual health services to ensure that screening levels remain high in those at highest risk. 
However, around 30% of women who had not attended cervical screening in the past 5 years 
reported attending ante-natal or sexual health (GUM) clinics in the past 5 years or obtaining 
contraceptives from clinical sources in the past year, suggesting missed opportunities to engage 
these women with cervical screening.  
Changes to the cervical screening programme are likely in coming years, due both to HPV 
immunisation effects on HPV epidemiology and the use of HPV testing in screening algorithms. HPV 
testing has already been introduced to help manage women with borderline and mildly abnormal 
cytology results. A pilot of HPV testing as the primary screening test (in place of cytology) is currently 
underway (46). It is unclear how changes will impact cervical screening uptake.  
To date, there are few data relating to HPV vaccination uptake in the routine cohorts by the 
variables we have explored. It will be important to study factors associated with routine HPV 
vaccination uptake in the same way. Uptake of cervical screening among women who have not 
received HPV vaccination should be studied as these women reach screening age.  
As some non-attenders for cervical screening seem to be at low risk for HR-HPV, tailored approaches 
may be appropriate to increase screening among higher-risk women. Socio-economic markers and 
smoking were associated with HR-HPV positivity, non-completion of catch-up HPV vaccination and 
non-attendance for cervical screening. This highlights the importance of general practice considering 
all aspects of the cervical cancer prevention pathway: vaccination, healthy lifestyle advice and 
cervical screening. To avoid a potential widening of cervical cancer disparities in the catch-up age 
cohorts, special efforts may be warranted to ensure that those who missed catch-up HPV 
vaccination are engaged by the cervical screening programme.  
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Table 1: Factors associated with high-risk HPV in urine in sexually-experienced women aged 
16-44 years 
  % (95%CI) OR (95%CI) 
Age 
adjusted 
OR (95%CI) 
Denom. 
(unwt, wt) 
a 
All 15.9% (14.4-17.5) -       2569, 2189 
Socio-demographic characteristics               
Age (years)     p<0.0001         
16-19 24.40% (20.0-29.3) 1 -     377, 203 
20-24 26.60% (22.8-30.8) 1.13 (0.82-1.56)     580, 370 
25-34 15.60% (13.4-18.2) 0.58 (0.42-0.79)     1108, 779 
35-44 9.30% (7.1-12.2) 0.32 (0.22-0.47)    504, 837 
Relationship status at interview     p<0.0001   p<0.0001     
Living with a partner 11.20% (9.5-13.1) 1 - 1 - 1256, 1357 
In a steady relationship (but not living with a 
partner) 26.00% (22.2-30.1) 2.79 (2.13-3.66) 1.95 (1.44-2.65) 602, 360 
Previously in a live-in partnership 19.90% (15.3-25.4) 1.97 (1.37-2.84) 1.92 (1.34-2.76) 353, 240 
Not in a steady relationship (never lived with 
partner) 23.90% (18.8-29.8) 2.49 (1.76-3.54) 1.65 (1.13-2.42) 355, 229 
Index of Multiple Deprivation (quintiles) b     P=0.0238   p=0.0578     
1-2 (least deprived) 13.50% (11.2-16.1) 1 - 1 - 873, 778 
3 15.00% (11.8-18.7) 1.13 (0.80-1.58) 1.12 (0.80-1.57) 502, 439 
4-5 (most deprived) 18.30% (15.9-20.9) 1.43 (1.10-1.87) 1.37 (1.05-1.80) 1194, 973 
Academic qualifications c     p=0.6717   p=0.1250      
No academic qualifications 15.10% (10.5-21.4) 0.99 (0.63-1.56) 1.13 (0.72-1.77) 215, 191 
Academic qualifications typically gained at age 16 16.70% (14.1-19.6) 1.12 (0.87-1.44) 1.3 (1.01-1.68) 877, 748 
Studying for/attained further academic 
qualifications 15.20% (13.3-17.4) 1 - 1 - 1348, 1157 
Housing tenure     p<0.0001   p=0.0011     
Own outright 14.30% (10.0-19.9) 1.38 (0.88-2.16) 1.15 (0.72-1.81) 218, 201 
Buying with a mortgage or loan d 10.80% (8.9-13.0) 1 - 1 - 911, 912 
 Rent it 20.50% (18.0-23.1) 2.13 (1.64-2.78) 1.71 (1.30-2.26) 1325, 996 
 Lives rent free 24.10% (16.6-33.8) 2.64 (1.59-4.38) 1.53 (0.91-2.56) 106, 74 
Respondent's National Statistics Socio-Economic 
Classification      p<0.0001   p=0.0009     
Managerial & prof occupations 10.30% (8.3-12.7) 1 - 1 - 709, 714
Intermediate occupations 16.60% (13.0-21.1) 1.74 (1.21-2.52) 1.60 (1.11-2.30) 464, 423 
Semi-routine/routine occupations 18.50% (15.6-21.7) 1.98 (1.45-2.69) 1.57 (1.14-2.17) 780, 617 
No job (10+ hrs/week) or not in last 10 years 22.50% (16.6-29.8) 2.53 (1.62-3.96) 2.08 (1.31-3.31) 210, 173 
Student in full-time education 19.80% (15.8-24.6) 2.16 (1.50-3.11) 1.01 (0.66-1.55) 398, 256 
Ethnic group e     p=0.0061   p=0.0150     
White 16.20% (14.6-18.0) 1 - 1 - 2312, 1914 
Mixed 29.70% (19.4-42.7) 2.18 (1.24-3.85) 2.00 (1.09-3.67) 74, 58 
Asian/Asian British 7.00% (2.9-15.5) 0.39 (0.16-0.95) 0.40 (0.17-0.97) 82, 114 
Black/Black British 12.60% (6.8-22.0) 0.74 (0.38-1.46) 0.69 (0.36-1.32) 77, 77 
Religion     p=0.0286   p=0.2671     
None 17.70% (15.7-20.0) 1 - 1 - 1509, 1189 
Christian - Church of England/Anglican 9.80% (6.2-15.2) 0.51 (0.30-0.85) 0.7 (0.42-1.19) 220, 235 
Christian - Roman Catholic 14.20% (10.3-19.3) 0.77 (0.52-1.14) 0.84 (0.57-1.25) 261, 226 
Christian - other 17.00% (13.4-21.5) 0.96 (0.69-1.32) 1.01 (0.73-1.39) 457, 396 
Non-Christian 10.40% (5.9-17.7) 0.54 (0.29-1.01) 0.57 (0.31-1.05) 122, 142 
Sexual identity     p=0.2447   p=0.1893     
Heterosexual/straight 16.10% (14.5-17.8) 1 - 1 - 2457, 2108 
 Gay/lesbian/bisexual 11.40% (6.1-20.1) 0.67 (0.34-1.32) 0.62 (0.31-1.26) 107, 79 
Health behaviours               
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Smoking status     p<0.0001   p<0.0001     
Non/Ex-smoker 12.9% (11.4-14.7) 1 - 1 - 1702, 1568 
Current smoker 23.4% (20.1-26.9) 2.05 (1.61-2.60) 1.91 (1.49-2.43) 867, 622 
Frequency of binge drinking f     p=0.0001   p=0.0011     
Never / less than monthly 13.90% (12.2-15.7) 1 - 1 - 1730, 1573 
Monthly 19.10% (15.6-23.2) 1.47 (1.10-1.96) 1.31 (0.98-1.75) 484, 355 
Weekly or more often 23.80% (19.1-29.3) 1.94 (1.42-2.66) 1.80 (1.31-2.47) 355, 261 
Sexual behaviours               
Age at first heterosexual sex (years)     p<0.0001   p=0.0059     
18+ 11.0% (8.5-14.0) 1 - 1 - 577, 642 
17 12.9% (9.8-16.7) 1.20 (0.79-1.82) 1.18 (0.78-1.80) 432, 419 
16 20.5% (17.2-24.3) 2.10 (1.48-2.97) 1.78 (1.24-2.56) 659, 517 
<16 20.2% (17.4-23.4) 2.06 (1.47-2.89) 1.65 (1.17-2.34) 859, 577 
Number of sexual partners, lifetime g     p<0.0001   p<0.0001     
1 4.2% (2.4-7.2) 1 - 1 - 342, 361 
2 11.3% (7.5-16.5) 2.89 (1.40-5.96) 2.74 (1.32-5.69) 234, 213 
3-4 13.7% (10.6-17.5) 3.60 (1.91-6.81) 3.71 (1.97-7.01) 441, 388 
5-9 17.2% (14.3-20.6) 4.74 (2.55-8.79) 5.67 (3.07-10.46) 709, 593 
10+ 24.0% (20.9-27.4) 7.19 (3.94-13.10) 9.35 (5.14-17.02) 822, 614 
No. of sexual partners, past 5 years g     p<0.0001   p<0.0001     
0/1 7.1% (5.7-8.9) 1 - 1 - 1162, 1258 
2 21.9% (17.5-26.9) 3.64 (2.52-5.25) 3.34 (2.29-4.86) 425, 316 
3-4 23.0% (19.0-27.4) 3.88 (2.77-5.42) 3.43 (2.45-4.79) 424, 290 
5+ 37.5% (32.7-42.7) 7.82 (5.63-10.86) 6.62 (4.68-9.38) 544, 313 
Number of sexual partners without a condom, 
past year g     p<0.0001   p<0.0001     
0 11.30% (8.5-14.8) 1 - 1 - 449, 405 
1 14.00% (12.3-15.9) 1.28 (0.91-1.80) 1.35 (0.96-1.90) 1741, 1566 
2+ 40.10% (33.9-46.5) 5.27 (3.49-7.95) 4.35 (2.87-6.60) 347, 193 
Sexual health & services               
Used hormonal contraception h, past year     p=0.0001   p=0.1711     
No 13.1% (11.1-15.5) 1 - 1 - 1172, 1137 
Yes 19.7% (17.5-22.1) 1.63 (1.28-2.07) 1.20 (0.92-1.55) 982, 1388 
Attended a sexual health (GUM) clinic, past 5 
years      p<0.0001   p<0.0001     
No 11.7% (10.2-13.4) 1 - 1 - 1779, 1686 
Yes 30.4% (26.8-34.2) 3.29 (2.62-4.14) 2.54 (2.00-3.23) 765, 484 
STI diagnosis i, past 5 years      p<0.0001   p<0.0001     
No 14.7% (13.2-16.4) 1 - 1 - 2316, 2038 
Yes 35.3% (29.2-41.9) 3.16 (2.33-4.28) 2.36 (1.76-3.16) 237, 134 
Genital warts diagnosis, ever     p=0.2095   p=0.0891     
No 15.8% (14.3-17.5) 1 - 1 - 2436, 2085 
Yes 20.2% (13.9-28.3) 1.35 (0.85-2.14) 1.47 (0.94-2.30) 117, 86 
a Participants who reported at least one lifetime sexual partner, with urine test results (unweighted, weighted) 
b Index of Multiple Deprivation (IMD) is a multi-dimensional measure of area (neighbourhood)-level 
deprivation based on the participant’s postcode. IMD scores for England, Scotland and Wales were adjusted 
before being combined and assigned to quintiles, using a method by Payne and Abel (Payne and Abel, 2012). 
c Participants aged ≥17 years 
d Includes 29 women paying part mortgage & part rent (shared ownership) 
e  Those of Chinese / Other ethnicity are excluded from the denominator due to small numbers 
f Binge drinking defined as having six units on one occasion  
g Includes both opposite-sex and same-sex partners 
h Defined as having used the oral contraceptive pill, hormonal IUD, injections, or implants 
i Defined as having been diagnosed with one of chlamydia, gonorrhoea, syphilis, genital herpes, genital warts, 
trichomonas, non-specific urethritis/non-gonococcal urethritis  
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Table 2:  Factors associated with non-attendance at cervical screening in the past 5 years in 
women aged 26-64 years  
 
Not in past 5 years Not screened vs. screened in past 5 years  
  % (95%CI) OR (95%CI) 
Age 
adjusted 
OR (95%CI) 
Denom. 
(unwt, wt) 
a 
All ages 8.9% (8.0-9.8)         5012, 4731 
Socio-demographic characteristics               
Age, years     p<0.0001         
26-29 14.9% (12.7-17.4) 2.28 (1.72-3.00)     1121, 547 
30-39 7.1% (5.9-8.7) 1 -     1605, 1312 
40-49 6.2% (4.9-8.0) 0.86 (0.61-1.21)     1107, 1404 
50-59 9.6% (7.8-11.9) 1.38 (1.01-1.90)     826, 1058 
60-64 13.4% (9.7-18.2) 2.01 (1.32-3.05)     353, 411 
Relationship status at interview     p<0.0001   p=0.0004     
Living with a partner 8.0% (7.0-9.1) 1 - 1 - 3151, 3476 
In a steady relationship (but not living with a 
partner) 8.4% (6.3-11.2) 1.06 (0.75-1.50) 1.04 (0.73 - 1.46) 585, 373 
Previously in a live-in partnership 11.5% (9.4-14.0) 1.50 (1.14-1.96) 1.43 (1.09 - 1.87) 1015, 717 
Not in a steady relationship (never lived with 
partner) 18.5% (13.1-25.4) 2.61 (1.71-3.99) 2.31 (1.49 - 3.57) 234, 145 
Index of Multiple Deprivation (quintiles) b  p<0.0001   p<0.0001   
1-2 (least deprived) 6.3% (5.2-7.6) 1 - 1 - 1885, 1938 
3 8.9% (7.1-11.2) 1.46 (1.06-2.00) 1.44 (1.05 - 1.98) 1003, 943 
4-5 (most deprived) 11.5% (10.1-13.2) 1.95 (1.52-2.50) 1.91 (1.48 - 2.47) 2124, 1850 
Academic qualifications     p<0.0001   p=0.0001     
No academic qualifications 14.1% (11.5-17.1) 2.04 (1.53-2.73) 1.95 (1.43 - 2.66) 751, 764 
Academic qualifications typically gained at age 16 8.1% (6.8-9.5) 1.09 (0.84-1.42) 1.16 (0.88 - 1.52) 1828, 1730 
Studying for/attained further academic 
qualifications 7.4% (6.3-8.7) 1 - 1 - 2278, 2102 
Housing tenure     p<0.0001   p<0.0001     
Own outright 9.6% (7.7-12.0) 1.77 (1.28-2.46) 1.34 (0.93 - 1.92) 868, 1034 
Buying with a mortgage or loan c 5.7% (4.7-6.9) 1 - 1 - 2092, 2118 
 Rent it 12.6% (11.0-14.3) 2.40 (1.86-3.08) 2.14 (1.65 - 2.78) 1967, 1505 
 Lives rent free 17.3% (9.4-29.8) 3.49 (1.70-7.19) 2.88 (1.44 - 5.77) 71, 59 
Respondent's National Statistics Socio-Economic Classification   p<0.0001   p<0.0001     
Managerial & prof occupations 6.4% (5.3-7.7) 1 - 1 - 1868, 1810 
Intermediate occupations 7.0% (5.5-8.8) 1.10 (0.80-1.53) 1.07 (0.77 - 1.49) 1160, 1081 
Semi-routine/routine occupations 11.8% (10.0-13.9) 1.96 (1.49-2.59) 1.88 (1.42 - 2.49) 1361, 1249 
No job (10+ hrs/week) or not in last 10 years 14.8% (11.4-18.9) 2.54 (1.77-3.65) 2.40 (1.66 - 3.47) 475, 474 
Student in full-time education 9.5% (5.1-17.1) 1.55 (0.77-3.11) 1.32 (0.67 - 2.62) 124, 95 
Ethnic group      p=0.0066   p=0.0052     
White 8.3% (7.4-9.2) 1 - 1 - 4415, 4155 
Mixed 11.7% (5.7-22.4) 1.46 (0.68-3.17) 1.49 (0.68 - 3.25) 89, 72 
Asian/Asian British 15.1% (10.9-20.6) 1.97 (1.32-2.93) 1.96 (1.32 - 2.90) 254, 256 
Black/Black British 11.8% (6.8-19.6) 1.48 (0.81-2.71) 1.62 (0.88 - 2.97) 174, 176 
Other 12.5% (6.5-22.7) 1.58 (0.78-3.24) 1.52 (0.73 - 3.16) 69, 63 
Religion     p=0.0076   p=0.0049     
None 9.4% (8.2-10.9) 1 - 1 - 2330, 2052 
Christian - Church of England/Anglican 6.3% (4.8-8.4) 0.65 (0.46-0.92) 0.60 (0.42 - 0.86) 832, 906 
Christian - Roman Catholic 7.9% (5.9-10.6) 0.83 (0.58-1.19) 0.80 (0.55 - 1.16) 582, 558 
Christian - other 9.2% (7.2-11.7) 0.97 (0.72-1.32) 0.93 (0.68 - 1.28) 930, 903 
Muslim 13.9% (8.8-21.1) 1.55 (0.91-2.63) 1.50 (0.88 - 2.56) 160, 152 
Hindu 19.6% (11.2-32.1) 2.34 (1.20-4.57) 2.21 (1.13 - 4.32) 68, 57 
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Other 8.6% (3.8-18.5) 0.91 (0.38-2.18) 0.91 (0.40 - 2.08) 102, 94 
Sexual identity     p=0.0271   p=0.0234     
Heterosexual/straight 8.70% (7.9-9.7) 1 - 1 - 4849, 4599 
 Gay/lesbian 20.90% (11.1-35.7) 2.76 (1.31-5.78) 2.94 (1.36-6.38) 63, 56 
Bisexual 8.30% (3.9-16.5) 0.94 (0.43-2.05) 0.93 (0.44-1.98) 75, 53 
Health behaviours               
Smoking status     p<0.0001   p<0.0001     
Non/Ex-smoker 7.5% (6.6-8.5) 1 - 1 - 3700, 3646 
Current smoker 13.5% (11.5-15.7) 1.92 (1.54-2.40) 1.97 (1.57 - 2.47) 1312, 1085 
Frequency of binge drinking d     p=0.0277   p=0.0473     
Never / less than monthly 9.5% (8.5-10.6) 1 - 1 - 3769, 3636 
Monthly 6.7% (5.0-9.0) 0.69 (0.49-0.96) 0.69 (0.49 - 0.97) 664, 568 
Weekly or more often 7.1% (5.3-9.4) 0.73 (0.52-1.02) 0.77 (0.55 - 1.09) 578, 527 
Sexual behaviours               
Age at first heterosexual sex (years)     p=0.3000   p=0.5485     
18+ 9.70% (8.3-11.2) 1 - 1 - 1971, 2033 
16/17 8.20% (6.9-9.7) 0.83 (0.65-1.06) 0.89 (0.69 - 1.14) 1943, 1825 
<16 8.40% (6.7-10.5) 0.86 (0.64-1.15) 0.87 (0.64 - 1.18) 1040, 812 
No. of sexual partners, lifetime e     p=0.0612   p=0.2391     
1 11.4% (9.3-13.9) 1 - 1 - 832, 923 
2 9.4% (7.0-12.4) 0.80 (0.54-1.19) 0.81 (0.55 - 1.21) 468, 478 
3-4 8.5% (6.8-10.6) 0.72 (0.51-1.02) 0.77 (0.54 - 1.09) 920, 890 
5-9 8.0% (6.5-9.9) 0.68 (0.49-0.94) 0.74 (0.54 - 1.03) 1338, 1246 
10+ 7.5% (6.0-9.3) 0.63 (0.45-0.87) 0.68 (0.48 - 0.96) 1367, 1105 
No. of sexual partners, past 5 years e     p<0.0001   p<0.0001     
0 19.3% (15.0-24.5) 2.72 (1.94-3.82) 2.45 (1.67-3.61) 358, 342 
1 8.1% (7.1-9.2) 1 - 1 - 3133, 3311 
2 8.2% (6.1-10.9) 1.02 (0.72-1.45) 0.94 (0.66-1.34) 625, 471 
3-4 7.1% (5.1-9.8) 0.87 (0.60-1.25) 0.73 (0.50-1.05) 489, 328 
5+ 8.2% (5.6-12.0) 1.02 (0.66-1.58) 0.77 (0.49-1.22) 349, 216 
No. of sexual partners without a condom, past year e  p<0.0001   p<0.0001   
0 14.10% (12.0-16.6) 1 - 1 - 1263, 1136 
1 7.10% (6.2-8.1) 0.46 (0.37-0.59) 0.48 (0.38 - 0.62) 3420, 3358 
2+ 8.20% (5.0-12.9) 0.54 (0.31-0.93) 0.50 (0.28 - 0.89) 259, 163 
Health-related factors               
Used hormonal contraception f, past year  p=0.0001   p<0.0001   
No 9.8% (8.7-10.9) 1 - 1 - 3369, 3489 
Yes 6.3% (5.1-7.6) 0.62 (0.48-0.79) 0.53 (0.41 - 0.69) 1573, 1168 
Ever attended a sexual health (GUM) clinic   p=0.0002   p<0.0001   
No 9.7% (8.7-10.8) 1 - 1 - 3611, 3636 
Yes 6.0% (4.8-7.5) 0.60 (0.46-0.78) 0.53 (0.40 - 0.69) 1353, 1041 
Ever diagnosed with a STI g     p=0.0004   p=0.0002     
No (or only thrush) 9.5% (8.6-10.6) 1 - 1 - 4080, 3958 
Yes (excluding thrush) 5.1% (3.7-7.1) 0.51 (0.35-0.74) 0.49 (0.33 - 0.71) 882, 717 
STI risk: to self     p=0.0377   p=0.0200     
Greatly at risk / Quite a lot 5.5% (2.9-10.0) 1 - 1 - 130, 97 
Not very much 7.1% (5.6-9.1) 1.33 (0.65-2.71) 1.34 (0.67 - 2.67) 903, 715 
Not at all at risk 9.3% (8.3-10.3) 1.78 (0.92-3.44) 1.83 (0.97 - 3.48) 3958, 3900 
                
All women aged 26-44 who haven't had a 
hysterectomy & who provided a urine sample 10.6% (8.7-12.8)         
1474, 1512 
h 
1+ high-risk HPV type(s)     p=0.2062   p=0.2775     
Negative 10.1% (8.1-12.5) 1 - 1 - 1243, 1329 
Positive 13.7% (9.0-20.5) 1.42 (0.83-2.44) 1.35 (0.79 - 2.31) 231, 184 
25 
a Participants who haven't had a hysterectomy & who reported at least 1 lifetime sexual partner (unweighted, 
weighted) 
b Index of Multiple Deprivation (IMD) is a multi-dimensional measure of area (neighbourhood)-level 
deprivation based on the participant’s postcode. IMD scores for England, Scotland and Wales were adjusted 
before being combined and assigned to quintiles, using a method by Payne and Abel (Payne and Abel, 2012). 
c Includes 46 women paying part mortgage & part rent (shared ownership) 
d Binge drinking defined as having six units on one occasion  
e Includes both opposite-sex and same-sex partners 
f Defined as having used the oral contraceptive pill, hormonal IUD, injections, or implants 
g Defined as having been diagnosed with one of chlamydia, gonorrhoea, syphilis, genital herpes, genital warts, 
trichomonas, non-specific urethritis/non-gonococcal urethritis 
h Participants aged 26-44 years who haven't had a hysterectomy, who reported at least 1 lifetime sexual 
partner & who provided a urine sample 
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Table 3: Key characteristics of women who have not attended for cervical screening in the 
past 5 years, by number of lifetime partners  
 Not attended for screening in past 5 years 
 All not attended 1 lifetime partner a 2+ lifetime partners a
 (100%) (25%) (75%) 
 % (95%CI) % (95%CI) % (95%CI)
Denom. (unweighted, weighted) 496, 420 111, 105 385, 314
Age, years   
26-29 19.4% (16.3-22.9) 18.4% (12.6-26.0) 19.8% (16.3-23.8)
30-39 22.3% (18.5-26.7) 26.5% (18.3-36.6) 21.0% (16.8-25.9)
40-49 20.8% (16.6-25.8) 14.3% (7.2-26.3) 23.0% (18.2-28.7)
50-59 24.3% (19.9-29.3) 20.3% (12.4-31.5) 25.6% (20.5-31.5)
60-64 13.1% (9.6-17.6) 20.6% (12.5-31.9) 10.6% (7.1-15.5)
Index of Multiple Deprivation (quintiles) c p=0.4394 b  
1-2 (least deprived) 29.1% (24.4-34.2) 28.8% (20.3-39.2) 29.1% (23.8-35.1)
3 20.0% (16.0-24.7) 15.7% (10.0-23.9) 21.5% (16.7-27.2)
4-5 (most deprived) 50.9% (45.7-56.1) 55.5% (44.9-65.6) 49.4% (43.4-55.4)
Academic qualifications p=0.1289 b  
No academic qualifications 26.7% (22.1-31.8) 34.7% (24.2-46.9) 24.1% (19.4-29.7)
Academic qualifications typically 
gained at age 16 34.6% (29.6-39.9) 26.4% (17.4-38.0) 37.2% (31.5-43.2) 
Studying for/attained further 
academic qualifications 38.7% (33.6-44.1) 38.9% (28.4-50.6) 38.7% (32.9-44.8) 
Ethnic group  p<0.0001 b  
White 82.0% (77.5-85.8) 59.3% (47.9-69.8) 89.6% (85.3-92.7)
Mixed 2.0% (1.0-4.1) 1.4% (0.3-5.8) 2.2% (1.0-4.9)
Asian/Asian British 9.2% (6.5-12.8) 25.5% (17.2-36.1) 3.7% (2.1-6.6)
Black/Black British 4.9% (2.8-8.5) 9.4% (3.8-21.2) 3.5% (1.7-6.9)
Other 1.9% (1.0-3.5) 4.5% (1.9-9.9) 1.0% (0.4-2.7)
Smoking status p=0.0022 b  
Non/Ex-smoker 65.1% (60.2-69.7) 79.7% (68.9-87.4) 60.2% (54.6-65.6)
Current smoker 34.9% (30.3-39.8) 20.3% (12.6-31.1) 39.8% (34.4-45.4)
Age at first heterosexual sex (years) p<0.0001 b  
18+ 47.4% (42.4-52.6) 81.6% (71.3-88.8) 36.1% (30.6-41.9)
16/17 36.1% (31.2-41.2) 17.5% (10.4-27.9) 42.3% (36.5-48.3)
<16 16.5% (13.1-20.5) 0.9% (0.3-2.9) 21.7% (17.3-26.8)
Sexual partner, past 5 years a p=0.2239 b  
No 15.9% (12.2-20.3) 20.30% (12.5-31.4) 14.40% (10.6-19.2)
Yes 84.1% (79.7-87.8) 79.70% (68.6-87.5) 85.60% (80.8-89.4)
Denom. (unwt, wt) d 148, 160 31, 47 117, 112
1+ high-risk HPV type(s) p=0.0216 b  
Negative 84.2% (76.2-89.8) 94.80% (82.8-98.6) 79.70% (69.5-87.1)
Positive 15.8% (10.2-23.8) 5.20% (1.4-17.2) 20.30% (12.9-30.5)
a Includes both opposite-sex and same-sex partners       
b P-values for comparison between non-attenders with 1 and 2+ lifetime partners   
c Index of Multiple Deprivation (IMD) is a multi-dimensional measure of area (neighbourhood)-level 
deprivation based on the participant’s postcode. IMD scores for England, Scotland and Wales were 
adjusted before being combined and assigned to quintiles, using a method by Payne and Abel (Payne 
and Abel, 2012).       
d Non-attenders aged 26-44 years who provided a urine sample  
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Table 4: Factors associated with non-completion of HPV catch-up vaccination 
  Not completed Not completed vs. completed 
Denom. 
(unwt, 
wt)   % (95%CI) OR (95%CI) 
Age 
adjusted 
OR (95%CI) 
All eligible for HPV catch-up vaccination 
programme  38.50% (35.3-41.9)         1050, 562 
Socio-demographic factors               
Age at interview (years)     p<0.0001         
16-17 28.0% (23.2-33.4) 1 -     394, 195 
18-19 41.7% (36.7-47.0) 1.84 (1.33-2.56)     449, 241 
20-24 48.7% (41.3-56.1) 2.44 (1.64-3.63)     207, 125 
School year at eligibility for HPV vaccination programme   p<0.0001   p=0.0060     
14 (Y10/S3) 27.1% (20.1-35.3) 1 - 1 - 153, 78 
15 (Y11/S4) 26.8% (21.1-33.3) 0.99 (0.61-1.59) 1.01 (0.62-1.65) 244, 123 
16 (Y12/S5) 35.8% (29.5-42.6) 1.50 (0.94-2.39) 1.57 (0.90-2.74) 238, 117 
17 (Y13/S6 or post school) 49.4% (44.1-54.8) 2.64 (1.69-4.10) 2.87 (1.39-5.95) 415, 243 
Grouped government office region     p<0.0001   p<0.0001     
Rest of England 36.4% (32.7-40.2) 1 - 1 - 803, 421 
London 62.4% (52.3-71.5) 2.90 (1.87-4.50) 2.76 (1.77-4.30) 100, 66 
Scotland 19.8% (13.1-28.8) 0.43 (0.26-0.72) 0.41 (0.24-0.70) 89, 46 
Wales 44.4% (31.0-58.6) 1.4 (0.78-2.48) 1.31 (0.74-2.35) 58, 29 
Index of Multiple Deprivation (quintiles) a     p<0.0001   p=0.0001     
1-2 (least deprived) 30.1% (25.3-35.4) 1 - 1 - 393, 210 
3 36.7% (29.4-44.7) 1.34 (0.90-2.01) 1.35 (0.90-2.04) 209, 116 
4-5 (most deprived) 46.9% (42.0-51.9) 2.05 (1.50-2.81) 1.99 (1.44-2.74) 448, 236 
Parents social class     p=0.0308   p=0.0285     
I/II/III 35.1% (31.2-39.2) 1 - 1 - 714, 385 
IV/V 44.9% (37.0-53.1) 1.51 (1.04-2.19) 1.52 (1.05-2.21) 196, 103 
Academic qualifications b     p<0.0001   p<0.0001     
No academic qualifications 75.2% (55.9-87.9) 6.04 (2.63-13.85) 5.84 (2.50-13.62) 39, 18 
Academic qualifications typically gained at age 16 57.2% (49.3-64.7) 2.66 (1.85-3.83) 2.52 (1.75-3.65) 188, 92 
Studying for/attained further academic 
qualifications 33.4% (29.5-37.6) 1 - 1 - 650, 361 
Ethnic group     p=0.0015   p=0.0001     
White 36.3% (32.9-39.7) 1 - 1 - 937, 491 
Non-white 54.1% (43.5-64.5) 2.07 (1.32-3.25) 2.01 (1.29-3.13) 113, 71 
Health behaviours               
Smoking status     p<0.0001   p<0.0001     
Non/ex-smoker 31.8% (28.3-35.7) 1 - 1 - 737, 400 
Current smoker 55.0% (48.9-61.0) 2.62 (1.95-3.53) 2.61 (1.93-3.55) 313, 162 
Frequency of binge drinking c     p=0.0665   p=0.1886     
Never / less than monthly 36.8% (32.9-41.0) 1 - 1 - 712, 376 
Monthly 36.9% (30.0-44.5) 1.00 (0.71-1.43) 0.90 (0.62-1.30) 200, 107 
Weekly or more often 48.4% (39.4-57.6) 1.61 (1.07-2.42) 1.41 (0.92-2.15) 137, 78 
Sexual behaviours (all eligible for catch-up vaccination)      
Number of sexual partners, lifetime d     p<0.0001   p=0.0107     
0 24.50% (18.4-31.7) 0.62 (0.38-1.01) 0.72 (0.43-1.18) 205, 109 
1 34.40% (27.1-42.5) 1 - 1 - 203, 113 
2 37.60% (29.1-46.8) 1.15 (0.69-1.89) 1.12 (0.68-1.84) 147, 77 
3-4 39.60% (31.6-48.2) 1.25 (0.77-2.03) 1.22 (0.75-2.00) 171, 93 
5+ 49.90% (43.6-56.1) 1.89 (1.23-2.91) 1.70 (1.09-2.63) 317, 167 
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All eligible for HPV catch-up vaccination 
programme with 1+ lifetime partner d  41.90% (38.3-45.6)         843, 451 
Sexual behaviours (those with 1+ lifetime partner)       
Had heterosexual sex before 16      p=0.0088   p=0.0014     
No 37.50% (32.7-42.6) 1 - 1 - 456, 252 
Yes 47.70% (42.0-53.4) 1.52 (1.11-2.07) 1.68 (1.22-2.30) 355, 181 
Number of sexual partners, past year d     p=0.3294   p=0.2689     
0/1 39.70% (35.0-44.6) 1 - 1 - 475, 260 
2 44.80% (36.2-53.6) 1.23 (0.82-1.84) 1.28 (0.85-1.93) 156, 78 
3+ 45.70% (38.2-53.3) 1.28 (0.89-1.84) 1.3 (0.90-1.88) 203, 108 
Number of sexual partners without a condom, past year d p=0.0092  p=0.0065   
0 38.80% (31.0-47.2) 1 - 1 - 196, 106 
1 39.60% (34.7-44.7) 1.03 (0.68-1.56) 1.03 (0.69-1.55) 443, 238 
2+ 53.10% (45.1-60.9) 1.79 (1.13-2.83) 1.83 (1.16-2.88) 185, 98 
Health-related factors               
Used hormonal contraception, past year e     p<0.0001   p<0.0001     
No 54.30% (47.1-61.4) 1 - 1 - 235, 131 
Yes 36.40% (32.4-40.7) 0.48 (0.34-0.68) 0.47 (0.34-0.67) 570, 299 
Ever attended a sexual health (GUM) clinic      p=0.0044   p=0.0100     
No 37.20% (32.6-42.1) 1 - 1 - 462, 251 
Yes 47.80% (42.3-53.3) 1.54 (1.15-2.08) 1.49 (1.10-2.02) 377, 199 
Ever diagnosed with an STI (excluding thrush) f    p=0.1735   p=0.4147     
No (or only thrush) 41.00% (37.1-45.0) 1 - 1 - 730, 395 
Yes 48.50% (38.3-58.8) 1.36 (0.87-2.10) 1.2 (0.77-1.88) 109, 55 
Ever been pregnant     p<0.0001   p<0.0001     
No 35.40% (31.4-39.8) 1 - 1 - 633, 346 
Yes 63.40% (55.9-70.2) 3.15 (2.21-4.49) 2.94 (2.04-4.23) 210, 105 
All eligible for HPV catch-up vaccination 
programme with 1+ lifetime partner d who 
provided a urine sample 41.00% (36.1-46.1)         481, 273 
HPV markers in urine               
HPV positive     p=0.0302   p=0.0383     
HPV negative 36.00% (29.3-43.2) 1 - 1 - 253, 152 
HPV positive 47.20% (40.0-54.6) 1.6 (1.04-2.44) 1.57 (1.02-2.40) 228, 121 
1+ high-risk HPV type(s)     p=0.0003   p=0.0005     
Negative 35.30% (29.6-41.4) 1 - 1 - 347, 200 
Positive 56.60% (46.8-65.9) 2.39 (1.49-3.83) 2.33 (1.45-3.74) 134, 73 
a Index of Multiple Deprivation (IMD) is a multi-dimensional measure of area (neighbourhood)-level 
deprivation based on the participant’s postcode. IMD scores for England, Scotland and Wales were adjusted 
before being combined and assigned to quintiles, using a method by Payne and Abel (Payne and Abel, 2012). 
b Participants aged ≥17 years 
c Binge drinking defined as having six units on one occasion 
d Includes both opposite-sex and same-sex partners 
e Defined as having used the oral contacepive pill, hormonal IUD, injections, or implants 
f Defined as having been diagnosed with one of chlamydia, gonorrhoea, syphilis, genital herpes, genital warts, 
trichomonas, non-specific urethritis/non-gonococcal urethritis 
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Figure legends 
Figure 1: Uptake of cervical cancer interventions. A) Time since last cervical smear test by age 
group among women aged 26-74 years; B) HPV vaccination uptake by school year at eligibility for 
vaccination in either the routine (Year 8/S2) or catch-up programmes  
A) Women are eligible for cervical screening every 3-5 years depending on regional protocols (3 yearly to age 49 in England 
then 5 yearly to age 64; 3 yearly to age 64 in Wales and 3 yearly to age 60 in Scotland). 
Denominators exclude women who report having had a hysterectomy & those with no lifetime sexual partners. 
*All women in eligible age range for screening 
Denominators (unwt., wt.) are: 26-29 (1121, 547), 30-34 (1025,648), 35-39 (580,664), 40-44 (571, 710), 45-49 (536, 694), 
50-54 (427,553), 55-59 (399, 505), 60-64 (381,444), 65-69 (349, 387), 70-74 (225, 226), all eligible (5012, 4731) 
Percentage screened in past 5 years when women reporting a hysterectomy are included in the denominator (N=5372, 
5164) is 86.2%  
B) Denominators (unwt., wt.) are: Y10 (153, 78), Y11 (244, 123), Y12 (238, 117), Y13 (415, 243), All catch-up (1050, 562), 
Routine (44, 21)  
Figure 2: Relationship between risk factors for HR-HPV and uptake of cervical cancer programmes: 
(A) cervical screening and (B) HPV catch-up vaccination  
All ORs adjusted for age. 95%CIs for AORs exclude 1 with the exception of the association between hormonal contraception 
use and HR-HPV (see Tables 1, 2 and 4). 
Top right quadrant for each graph indicates increased risk of HR-HPV and lower uptake of cervical cancer prevention 
programme. The area of the bubble represents the size of the group as a proportion of those eligible for screening. Letters 
indicate reference groups: a) 1 lifetime sexual partner; b) non/ex-smoker; c) resident in 2 least deprived quintiles; d) 
White/White British; e) Not used hormonal contraception, past year; f) Never attended a sexual health (GUM) clinic 
Role of the sponsor 
The sponsors of the study had no role in study design and the collection, analysis and interpretation 
of data, or writing of the report. The corresponding author had full access to all the data in the study 
and had final responsibility for the decision to submit for publication. 
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